Pancreatic Cancer

>

Latest News

Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC
Mitigating NALIRIFOX-Related Diarrhea May Extend Survival in Metastatic PDAC

April 12th 2025

Post hoc analysis of the NAPOLI 3 trial suggests that proactively managing NALIRIFOX-induced diarrhea could allow patients with PDAC to remain on treatment longer.

Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer
Next-Generation Test Shows Sensitivity/Specificity in Pancreatic Cancer

March 26th 2025

Data from the phase 3 CABINET study support the approval of cabozantinib in patients with pancreatic neuroendocrine tumors.
FDA Approves Cabozantinib in Pancreatic/Extra-Pancreatic Neuroendocrine Tumors

March 26th 2025

OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC
OSE2101 Plus FOLFIRI Meets OS End Point in Advanced PDAC

March 12th 2025

CAN-2409/Valacyclovir Plus SOC Demonstrates Positive Survival in PDAC
CAN-2409/Valacyclovir Plus SOC Demonstrates Positive Survival in PDAC

February 27th 2025

Latest CME Events & Activities

Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®

View More

BURST CME™: Illuminating the Crossroads of Precision Medicine and Targeted Treatment Options in Metastatic CRC

View More

Fighting Disparities and Saving Lives: An Exploration of Challenges and Solutions in Cancer Care

View More

Community Practice Connections™: 14th Asia-Pacific Primary Liver Cancer Expert Meeting

View More

PER® Liver Cancer Tumor Board: How Do Evolving Data for Immune-Based Strategies in Resectable and Unresectable HCC Impact Multidisciplinary Patient Management Today… and Tomorrow?

View More

Show Me the Data™: Bridging Clinical Gaps Along the Continuum From Resectable, Early Stage to Advanced Gastric/Gastroesophageal Junction Cancers

View More

<1
...
1314151617